Progress in clinical neurosciences: The neuropathogenesis of HIV infection: Host-virus interaction and the impact of therapy

Canadian Journal of Neurological Sciences

Volumn 29, Issue 1, 2002, Pages 19-32

  Power, Christopher ^a   Gill, M J ^a,b   Johnson, R T ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMANTADINE; AMPRENAVIR; ARACHIDONIC ACID; CARBAMAZEPINE; CHEMOKINE; CN 1189; CYTOKINE; DIDANOSINE; GABAPENTIN; INDINAVIR; LAMIVUDINE; LEVODOPA; LEXIPAFANT; LOPINAVIR; MATRIX METALLOPROTEINASE; MEMANTINE; N (7 HYDROXY 2,2,4,6 TETRAMETHYL 1 INDANYL) 4 (3 METHOXYPHENYL) 1 PIPERAZINEACETAMIDE; NELFINAVIR; NEUROTROPHIN; NIMODIPINE; NUCLEOSIDE DERIVATIVE; RITONAVIR; SELEGILINE; STAVUDINE; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; ENVELOPE GENE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MOTOR DYSFUNCTION; NEUROPATHOLOGY; NEUROPROTECTION; PATHOGENESIS; POLYNEUROPATHY; PRIORITY JOURNAL; REVIEW; VIRUS CELL INTERACTION;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HUMANS; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS; VIRAL LOAD;

EID: 0036194251     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100001682     Document Type: Review

References (203)

1. The global impact of HIV infection and disease
2. HIV-1 associated dementia: Clinical features and pathogenesis
3. Neurologic manifestations of AIDS
4. Dementia in AIDS patients: Incidence and risk factors. Multicenter AIDS Cohort Study
5. Neuropsychological studies of asymptomatic human immunodeficiency virus- type-1 infected individuals
6. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force
7. The AIDS dementia complex: I. Clinical features
8. Parkinsonism with HIV infection
9. AIDS dementia complex with generalized myoclonus
10. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy
11. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998
12. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment
13. Neurocognitive impairment is an independent risk factor for death in HIV infection
14. Neurologic manifestations of HIV infection
15. Patterns of cerebral atrophy in HIV-1-infected individuals: Results of a quantitative MRI analysis
16. Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex
17. The AIDS dementia complex: II. Neuropathology
18. Pathology of HIV-1 infection of the central nervous system. A review
19. Loss of A1 adenosine receptors in human temporal lobe epilepsy
20. Pathologic features of AIDS encephalopathy in children: Evidence for LAV/HTLV-III infection of brain
21. Blood-brain barrier abnormalities in the acquired immunodeficiency syndrome: Immunohistochemical localization of serum proteins in postmortem brain
22. Cerebral white matter changes in acquired immunodeficiency syndrome dementia: Alterations of the blood-brain barrier
23. Apoptosis induced by HIV-1 infection of the central nervous system
24. Immunocytochemical quantitation of human immunodeficiency virus in the brain: Correlations with dementia
25. NFkappaB activation, TNF-alpha expression, and apoptosis in the AIDS- Dementia-Complex
26. Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains
27. Neuronal loss in the frontal cortex in HIV infection
28. Selective neuronal vulnerability in HIV encephalitis
29. Cortical dendritic pathology in human immunodeficiency virus encephalitis
30. Spinal cord disease in human immunodeficiency virus infection
31. Nonallelism for the audiogenic seizure prone (Asp1) and the aryl hydrocarbon receptor (Ahr) loci in mice
32. Nature and incidence of peripheral nerve syndromes in HIV infection
33. Peripheral neuropathy in HIV-1 infection
34. Neurological complications of HIV infection
35. Neuropathies in HIV infection
36. Cutaneous innervation in sensory neuropathies: Evaluation by skin biopsy
37. Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies
38. Neurovirological and neuroimmunological aspects of HIV infection
39. The molecular biology of human immunodeficiency virus type 1 infection
40. Human retroviruses and AIDS. A compilation and analysis of nucleic acid and amino acid sequences
41. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1
42. Identification of a major co-receptor for primary isolates of HIV-1
43. Reservoirs for HIV-1: Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy
44. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay
45. Possible viral cause of multiple sclerosis
46. Retroviral diseases of the nervous system: Pathogenic host response or viral gene-mediated neurovirulence?
47. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms
48. Human immunodeficiency virus and the brain: Investigation of virus load and neuropathologic changes in pre-AIDS subjects
49. Neuropathology of human immunodeficiency virus infection
50. Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone
51. Pathogenesis of lentivirus infections
52. HIV infection of human choroid plexus: A possible mechanism of viral entry into the CNS
53. Latent reservoirs of HIV: Obstacles to the eradication of virus
54. Comparisons of HIV-1 viral sequences in brain, choroid plexus and spleen: Potential role of choroid plexus in the pathogenesis of HIV encephalitis
55. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1
56. Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus
57. Sequence analysis of the V3 loop in brain and spleen of patients with HIV encephalitis
58. Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences
59. Cerebrospinal fluid beta chemokine concentrations in neurocognitively impaired individuals infected with human immunodeficiency virus type 1
60. The role of the blood-brain barrier in HIV infection of the central nervous system
61. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain
62. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage
63. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy
64. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients
65. Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry
66. Morphology and distribution of HIV-1 gp41-positive microglia in subacute AIDS encephalitis. Pattern of involvement resembling a multisystem degeneration
67. HTLV-III infection in brains of children and adults with AIDS encephalopathy
68. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: Identification by the combination of in situ polymerase chain reaction and immunohistochemistry
69. In situ detection of polymerase chain reaction-amplified HIV-1 nucleic acids and tumor necrosis factor-alpha RNA in the central nervous system
70. Human immunodeficiency virus infection of human brain capillary endothelial cells occurs via a CD4/galactosylceramide-independent mechanism
71. HIV-1 infection of human brain-derived microvascular endothelial cells in vitro
72. Human immunodeficiency virus in brain biopsies of patients with AIDS and progressive encephalopathy
73. HIV-1 infection induces differentiation of immature neural cells through autocrine tumor necrosis factor and nitric oxide production
74. HIV-1 infection of primary human neuroblasts
75. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
76. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1
77. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia
78. Specific tropism of HIV-1 for microglial cells in primary human brain cultures
79. Distinct HIV-1 env sequences are associated with neurotropism and neurovirulence
80. Infection of brain microglial cells by human immunodeficiency virus type 1 is CD4 dependent
81. V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1
82. Infection of primary human microglia and monocyte-derived macrophages with human immunodeficiency virus type 1 isolates: Evidence of differential tropism
83. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: Definition of critical amino acids involved in cell tropism
84. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
85. Chemokines and receptors in HIV encephalitis
86. Lymphotropic virions affect chemokine receptor-mediated neural signaling and apoptosis: Implications for human immunodeficiency virus type 1-associated dementia
87. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis
88. Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide
89. Characterization of a novel binding site for the human immunodeficiency virus type 1 envelope protein gp120 on human fetal astrocytes
90. Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages
91. Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo
92. Mosaic structure of the human immunodeficiency virus type 1 genome infecting lymphoid cells and the brain: Evidence for frequent in vivo recombination events in the evolution of regional populations
93. HIV-1 tat molecular diversity and induction of TNF-alpha: Implications for HIV-induced neurological disease
94. Expression directed from HIV long terminal repeats in the central nervous system of transgenic mice
95. In vivo compartmentalization of human immunodeficiency virus: Evidence from the examination of pol sequences from autopsy tissues
96. Human immunodeficiency virus type 1 clade A and neurotropism: Molecular evolution, recombination and co-receptor utilization
97. Human immunodeficiency virus type 1 subtypes differ in disease progression
98. Virtues of being faithful: Can we limit the genetic variation in human immunodeficiency virus?
99. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression
100. Investigation of the dynamics of the spread of human immunodeficiency virus to brain and other tissues by evolutionary analysis of sequences from the p17gag and env genes
101. Neurovirulence in feline immunodeficiency virus-infected neonatal cats is viral strain specific and dependent on systemic immune suppression
102. Neurological abnormalities associated with feline immunodeficiency virus infection
103. Pathogenesis of simian immunodeficiency virus encephalitis: Viral determinants of neurovirulence
104. Neurovirulent simian immunodeficiency virus replicates productively in endothelial cells of the central nervous system in vivo and in vitro
105. Lentiviral infection in the brain induce matrix metalloproteinase expression: The role of envelope diversity
106. Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients
107. Varied tropism of HIV-1 isolates derived from different regions of adult brain cortex discriminate between patients with and without AIDS dementia complex (ADC): Evidence for neurotropic HIV variants
108. PCR detection of host and HIV-1 sequences from archival brain tissue
109. Apoptosis induced by infection of primary brain cultures with diverse human immunodeficiency virus type 1 isolates: Evidence for a role of the envelope
110. Neurobiological aspects of human immunodeficiency virus infection: Neurotoxic mechanisms
111. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists
112. Neuronal injury due to HIV-1 envelope protein is blocked by anti-gp120 antibodies but not by anti-CD4 antibodies
113. gp120, a human immunodeficiency virus-1 coat protein, augments excitotoxic hippocampal injury in perinatal rats
114. The envelope glycoprotein of human immunodeficiency virus type 1 stimulates release of neurotoxins from monocytes
115. The human immunodeficiency virus-1 envelope protein gp120 binds through its V3 sequence to the glycine site of N-methyl-D-aspartate receptors mediating noradrenaline release in the hippocampus
116. Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome
117. The changing landscape of ischaemic brain injury mechanisms
118. Memantine prevents HIV coat protein-induced neuronal injury in vitro
119. HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures
120. Human immunodeficiency virus type 1 coat protein neurotoxicity mediated by nitric oxide in primary cortical cultures
121. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice
122. Cytokines and HIV envelope glycoprotein gp120 stimulate Na+/H+ exchange in astrocytes
123. HIV glycoprotein 120 enhances intercellular adhesion molecule-1 gene expression in glial cells. Involvement of Janus kinase/signal transducer and activator of transcription and protein kinase C signaling pathways
124. Immunologic NO synthase: Elevation in severe AIDS dementia and induction by HIV-1 gp41
125. Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic
126. The Tat protein of HIV-1 induces tumor necrosis factor-alpha production. Implications for HIV-1-associated neurological diseases
127. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon
128. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia
129. gp120 induces cell death in human neuroblastoma cells through the CXCR4 and CCR5 chemokine receptors
130. HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors
131. Decay characteristics of HIV-1-infected compartments during combination therapy
132. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome
133. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources
134. Quantitation of human immunodeficiency virus in brains of demented and nondemented patients with acquired immunodeficiency syndrome
135. Human immunodeficiency virus type 1 DNA and RNA load in brains of demented and nondemented patients with acquired immunodeficiency syndrome
136. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) p24 antigen levels in HIV-1-related dementia
137. AIDS dementia complex and HIV-1 brain infection: Clinical-virological correlations
138. Low levels of human immunodeficiency virus replication in the brain tissue of children with severe acquired immunodeficiency syndrome encephalopathy
139. Microglia as mediators of inflammatory and degenerative diseases
140. Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1
141. Human immunodeficiency virus-infected macrophages produce soluble factors that cause histological and neurochemical alterations in cultured human brains
142. HIV-1 and the developing human nervous system: In vivo and in vitro aspects
143. The neuropathogenesis of the AIDS dementia complex
144. Cytokine expression in the brain during the acquired immunodeficiency syndrome
145. Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia
146. Platelet-activating factor: A candidate human immunodeficiency virus type 1-induced neurotoxin
147. HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease
148. In vitro evidence for a dual role of tumor necrosis factor-alpha in human immunodeficiency virus type 1 encephalopathy
149. Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia
150. Toxicity of TNF alpha and platelet activating factor for human NT2N neurons: A tissue culture model for human immunodeficiency virus dementia
151. Increased expression of tumor necrosis factor-alpha receptors in the brains of patients with AIDS
152. Overexpression of nerve growth factor and basic fibroblast growth factor in AIDS dementia complex
153. Biochemical functions of a pool of arachidonic acid associated with triglycerides in human inflammatory cells
154. Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia
155. Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: Implications for the neuropathogenesis of HIV disease
156. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate
157. Kynurenine pathway enzymes in brain. Properties of enzymes and regulation of quinolinic acid synthesis
158. Tryptophan metabolism and brain function: Focus on kynurenine and other indole metabolites
159. Increased human immunodeficiency virus (HIV) type 1 DNA content and quinolinic acid concentration in brain tissues from patients with HIV encephalopathy
160. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: Relationship to clinical and neurological status
161. Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia
162. Matrix metalloproteinases and diseases of the CNS
163. Human immunodeficiency virus infection, inducible nitric oxide synthase expression, and microglial activation: Pathogenetic relationship to the acquired immunodeficiency syndrome dementia complex
164. Increased peroxynitrite activity in AIDS dementia complex: Implications for the neuropathogenesis of HIV-1 infection
165. Study of receptor-mediated neurotoxins released by HIV-1-infected mononuclear phagocytes found in human brain
166. Do chemokines mediate leukocyte recruitment in post-traumatic CNS inflammation?
167. Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus- associated dementia
168. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity
169. HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy
170. Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia
171. Potential role of CCR5 polymorphism in the development of AIDS dementia complex
172. Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex
173. CCR5 signal transduction in macrophages by human immunodeficiency virus and simian immunodeficiency virus envelopes
174. Polygenic and multifactorial disease gene association in man: Lessons from AIDS
175. Excitotoxins in neuronal apoptosis and necrosis
176. Neuronal density in the superior frontal and temporal gyri does not correlate with the degree of human immunodeficiency virus-associated dementia
177. Neocortical damage during HIV infection
178. Loss of neurons in the frontal cortex in AIDS brains
179. Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder
180. Neurodegeneration of somatostatin-immunoreactive neurons in HIV encephalitis
181. Apoptotic neurons in brains from paediatric patients with HIV-1 encephalitis and progressive encephalopathy
182. Neuronal apoptosis in HIV infection in adults
183. Neuronal apoptosis does not correlate with dementia in HIV infection but is related to microglial activation and axonal damage
184. Astrocyte apoptosis induced by HIV-1 transactivation of the c-kit protooncogene
185. Correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia
186. Human immunodeficiency virus type 1 and its coat protein gp120 induce apoptosis and activate JNK and ERK mitogen-activated protein kinases in human neurons
187. HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity
188. Human immunodeficiency virus-associated dementia
189. Neurological outcomes in late HIV infection: Adverse impact of neurological survival and protection effect of antiretroviral therapy
190. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy
191. Highly active antiretroviral treatment in HIV infection: Benefits for neuropsychological function
192. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment
193. Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS)
194. Abacavir in AIDS dementia complex: Efficacy and lessons for future trials
195. Selection of drug-resistant HIV
196. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
197. Brain-derived HIV-1 tat sequences from AIDS patients with dementia show increased molecular heterogeneity
198. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection
199. Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment
200. A phase I/II trial of nimodipine for HIV-related neurologic complications